Form 4: Cytek Biosciences SVP Philippe Busque Reports Stock Transactions
SEC Form 4 Filing
Philippe Busque, SVP at Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 20, 2024, Philippe Busque, SVP at Cytek Biosciences, had 5,464 Restricted Stock Units (RSUs) vest.
- Upon vesting, Busque exercised these RSUs, receiving 5,464 shares of Cytek Biosciences common stock.
- Simultaneously, 2,129 shares were withheld by Cytek Biosciences to cover tax obligations related to the RSU vesting at a price of $6.7.
- Following these transactions, Busque directly owns 3,335 shares of Cytek Biosciences common stock.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the issuance of new shares upon RSU vesting, potentially diluting existing ownership slightly.
Key Dates
| Date | Description |
|---|---|
| 03/20/2024 | Date of earliest transaction: vesting of Restricted Stock Units and tax withholding. |
| 03/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.